In colorectal carcinoma, EGFR (ErbB1) signaling remains a cornerstone of oncogenic drive, while the HER2 (ErbB2) and HER3 (ErbB3) axis has gained increasing recognition for its role in tumor progression, therapy resistance, and compensatory signaling when EGFR is inhibited. Here, ERBB3 is linked to neoplasm.